Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer

Gut and Liver

Volumn 7, Issue 6, 2013, Pages 629-641

  Park, Jung Jin ^a   Lee, Minyoung ^b  

^a Korea University   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Beta D galactoside alpha 2 6 sialyltransferase; Chemoresistance; Colorectal neoplasms; Neoplasm metastasis; Radioresistance

Indexed keywords

ACYLTRANSFERASE; ASPARAGINE; BETA1 INTEGRIN; ERLOTINIB; FLUOROURACIL DERIVATIVE; FOCAL ADHESION KINASE; GEFITINIB; GLYCOCONJUGATE; GLYCOPROTEIN; IRINOTECAN; LECTIN; MUCIN; N GLYCOLOYLNEURAMINIC ACID; OXALIPLATIN; PAXILLIN; PROTEIN KINASE B; SIALIC ACID DERIVATIVE; SIALIDASE; SIALOGLYCOPROTEIN; SIALYLTRANSFERASE; ST6 GAL I PROTEIN; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CELL ADHESION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CELLULAR SECRETION; CYTOSOL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GASTROINTESTINAL TRACT; HUMAN; LYSOSOME; METASTATIC COLORECTAL CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; SIALYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; VISCOSITY;

BETA-D-GALACTOSIDE ALPHA 2-6-SIALYLTRANSFERASE; CHEMORESISTANCE; COLORECTAL NEOPLASMS; NEOPLASM METASTASIS; RADIORESISTANCE;

ANTIGENS, CD; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIALIC ACIDS; SIALYLTRANSFERASES;

EID: 84888586398     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.6.629     Document Type: Review

References (165)

1. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol 2012;13:448-462.
2. Zoldoš V, Novokmet M, Bečeheli I, Lauc G. Genomics and epigenomics of the human glycome. Glycoconj J 2013;30:41-50.
3. Schachter H, Freeze HH. Glycosylation diseases: quo vadis? Biochim Biophys Acta 2009;1792:925-930.
4. Stanley P, Schachter H, Taniguchi N. N-glycans. In: Varki A, Cummings RD, Esko JD, et al., eds. Essentials of glycobiology. 2nd ed. New York: Cold Spring Harbor Laboratory Press, 2009:101-114.
5. Brockhausen I, Schachter H, Stanley P. O-GalNAc glycans. In: Varki A, Cummings RD, Esko JD, et al., eds. Essentials of glycobiology. 2nd ed. New York: Cold Spring Harbor Laboratory Press, 2009:115-128.
6. Miyagi T, Takahashi K, Hata K, Shiozaki K, Yamaguchi K. Sialidase significance for cancer progression. Glycoconj J 2012;29:567-577.
7. Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front Biosci (Landmark Ed) 2012;17:670-699.
8. Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev 2012;31:501-518.
9. Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta 2012;1820:1347-1353.
10. Varki A. Sialic acids in human health and disease. Trends Mol Med 2008;14:351-360.
11. Yamaguchi K, Shiozaki K, Moriya S, et al. Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase. PLoS One 2012;7:e41132.
12. Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 2007;87:851-857.
13. Varki A. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc Natl Acad Sci U S A 2010;107 Suppl 2:8939-8946.
14. Li Y, Chen X. Sialic acid metabolism and sialyltransferases: natural functions and applications. Appl Microbiol Biotechnol 2012;94:887-905.
15. Audry M, Jeanneau C, Imberty A, Harduin-Lepers A, Delannoy P, Breton C. Current trends in the structure-activity relationships of sialyltransferases. Glycobiology 2011;21:716-726.
16. Chen X, Varki A. Advances in the biology and chemistry of sialic acids. ACS Chem Biol 2010;5:163-176.
17. Tsuji S. Molecular cloning and functional analysis of sialyltransferases. J Biochem 1996;120:1-13.
18. Harduin-Lepers A, Recchi MA, Delannoy P. 1994, the year of sialyltransferases. Glycobiology 1995;5:741-758.
19. Datta AK. Comparative sequence analysis in the sialyltransferase protein family: analysis of motifs. Curr Drug Targets 2009;10:483-498.
20. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie 2001;83:727-737.
21. Lee HJ, Lee M, Kang CM, et al. Identification of possible candidate biomarkers for local or whole body radiation exposure in C57BL/6 mice. Int J Radiat Oncol Biol Phys 2007;69:1272-1281.
22. Hennet T, Chui D, Paulson JC, Marth JD. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci U S A 1998;95:4504-4509.
23. Stamenkovic I, Sgroi D, Aruffo A. CD22 binds to alpha-2,6- sialyltransferase-dependent epitopes on COS cells. Cell 1992;68:1003-1004.
24. Stamenkovic I, Sgroi D, Aruffo A, Sy MS, Anderson T. The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells. Cell 1991;66:1133-1144.
25. Collins BE, Smith BA, Bengtson P, Paulson JC. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol 2006;7:199-206.
26. Hedlund M, Ng E, Varki A, Varki NM. alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 2008;68:388-394.
27. Swindall AF, Londono-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Res 2013;73:2368-2378.
28. Shaikh FM, Seales EC, Clem WC, Hennessy KM, Zhuo Y, Bellis SL. Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms. Exp Cell Res 2008;314:2941-2950.
29. Dall'Olio F, Malagolini N, Chiricolo M. Beta-galactoside alpha2,6-sialyltransferase and the sialyl alpha2,6-galactosyl-linkage in tissues and cell lines. Methods Mol Biol 2006;347:157-170.
30. Chiricolo M, Malagolini N, Bonfiglioli S, Dall'Olio F. Phenotypic changes induced by expression of beta-galactoside alpha2,6 sialyltransferase I in the human colon cancer cell line SW948. Glycobiology 2006;16:146-154.
31. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 2005;65:4645-4652.
32. Birkenkamp-Demtroder K, Olesen SH, Sørensen FB, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005;54:374-384.
33. Zhu Y, Srivatana U, Ullah A, Gagneja H, Berenson CS, Lance P. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta 2001;1536:148-160.
34. Nemoto-Sasaki Y, Mitsuki M, Morimoto-Tomita M, Maeda A, Tsuiji M, Irimura T. Correlation between the sialylation of cell surface Thomsen-Friedenreich antigen and the metastatic potential of colon carcinoma cells in a mouse model. Glycoconj J 2001;18:895-906.
35. Lise M, Belluco C, Perera SP, Patel R, Thomas P, Ganguly A. Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma 2000;19:281-286.
36. Dall'Olio F, Chiricolo M, Ceccarelli C, Minni F, Marrano D, Santini D. Beta-galactoside alpha2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with Sambucus nigra agglutinin. Int J Cancer 2000;88:58-65.
37. Dall'Olio F. The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role. Glycoconj J 2000;17:669-676.
38. Murayama T, Zuber C, Seelentag WK, et al. Colon carcinoma glycoproteins carrying alpha 2,6-linked sialic acid reactive with Sambucus nigra agglutinin are not constitutively expressed in normal human colon mucosa and are distinct from sialyl-Tn antigen. Int J Cancer 1997;70:575-581.
39. Swindall AF, Bellis SL. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem 2011;286:22982-22990.
40. Sawada M, Moriya S, Saito S, et al. Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. Int J Cancer 2002;97:180-185.
41. Dall'Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J 2001;18:841-850.
42. Bresalier RS, Rockwell RW, Dahiya R, Duh QY, Kim YS. Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis. Cancer Res 1990;50:1299-1307.
43. Yue T, Haab BB. Microarrays in glycoproteomics research. Clin Lab Med 2009;29:15-29.
44. Medzihradszky KF. Characterization of protein N-glycosylation. Methods Enzymol 2005;405:116-138.
45. Varki A, Cummings RD, Esko JD, et al. Symbol nomenclature for glycan representation. Proteomics 2009;9:5398-5399.
46. Varki A, Schauer R. Sialic acids. In: Varki A, Cummings RD, Esko JD, et al., eds. Essentials of glycobiology. 2nd ed. New York: Cold Spring Harbor Laboratory Press, 2009.
47. Varki A. Diversity in the sialic acids. Glycobiology 1992;2:25-40.
48. Yin J, Hashimoto A, Izawa M, et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 2006;66:2937-2945.
49. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009;19:507-514.
50. Schauer R. Achievements and challenges of sialic acid research. Glycoconj J 2000;17:485-499.
51. Jass JR, Walsh MD. Altered mucin expression in the gastrointestinal tract: a review. J Cell Mol Med 2001;5:327-351.
52. Jass Jr. Mucin core proteins as differentiation markers in the gastrointestinal tract. Histopathology 2000;37:561-564.
53. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-99.
54. Saez C, Japon MA, Poveda MA, Segura DI. Mucinous (colloid) adenocarcinomas secrete distinct O-acylated forms of sialomucins: a histochemical study of gastric, colorectal and breast adenocarcinomas. Histopathology 2001;39:554-560.
55. Yamaoka Y. Increasing evidence of the role of Helicobacter pylori SabA in the pathogenesis of gastroduodenal disease. J Infect Dev Ctries 2008;2:174-181.
56. Lewis AL, Lewis WG. Host sialoglycans and bacterial sialidases: a mucosal perspective. Cell Microbiol 2012;14:1174-1182.
57. Aspholm M, Olfat FO, Norden J, et al. SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathog 2006;2:e110.
58. Shen Y, Kohla G, Lrhorfi AL, et al. O-acetylation and de-O-acetylation of sialic acids in human colorectal carcinoma. Eur J Biochem 2004;271:281-290.
59. Shen Y, Tiralongo J, Kohla G, Schauer R. Regulation of sialic acid O-acetylation in human colon mucosa. Biol Chem 2004;385:145-152.
60. Corfield AP, Wagner SA, Clamp JR, Kriaris MS, Hoskins LC. Mucin degradation in the human colon: production of sialidase, sialate O-acetylesterase, N-acetylneuraminate lyase, arylesterase, and glycosulfatase activities by strains of fecal bacteria. Infect Immun 1992;60:3971-3978.
61. Corfield AP, Myerscough N, Warren BF, Durdey P, Paraskeva C, Schauer R. Reduction of sialic acid O-acetylation in human colonic mucins in the adenoma-carcinoma sequence. Glycoconj J 1999;16:307-317.
62. Kitazume S, Suzuki M, Saido TC, Hashimoto Y. Involvement of proteases in glycosyltransferase secretion: Alzheimer's beta-secretase-dependent cleavage and a following processing by an aminopeptidase. Glycoconj J 2004;21:25-29.
63. Kitazume S, Saido TC, Hashimoto Y. Alzheimer's beta-secretase cleaves a glycosyltransferase as a physiological substrate. Glycoconj J 2004;20:59-62.
64. Alhadeff JA, Holzinger RT. Purification of human liver glycoprotein sialyltransferase by affinity chromatography. J Biochem Biophys Methods 1982;6:229-233.
65. Ratnam S, Nagpurkar A, Mookerjea S. Characterization of serum, liver, and intestinal sialyltransferases from rats treated with colchicine. Biochem Cell Biol 1987;65:183-187.
66. Kessel D, Allen J. Elevated plasma sialyltransferase in the cancer patient. Cancer Res 1975;35:670-672.
67. Nakamura R, Tsunemitsu A. The presence of cytidine 5'-monophosphosialic acid: glycoprotein sialyltransferase in human saliva. J Dent Res 1975;54:188.
68. Angata K, Fukuda M. Polysialyltransferases: major players in polysialic acid synthesis on the neural cell adhesion molecule. Biochimie 2003;85:195-206.
69. Spiro MJ, Spiro RG. Glycoprotein biosynthesis: studies on thyroglobulin. Thyroid sialyltransferase. J Biol Chem 1968;243:6520-6528.
70. Maksimovic J, Sharp JA, Nicholas KR, Cocks BG, Savin K. Conservation of the ST6Gal I gene and its expression in the mammary gland. Glycobiology 2011;21:467-481.
71. Dalziel M, Huang RY, Dall'Olio F, Morris JR, Taylor-Papadimitriou J, Lau JT. Mouse ST6Gal sialyltransferase gene expression during mammary gland lactation. Glycobiology 2001;11:407-412.
72. Paulson JC, Beranek WE, Hill RL. Purification of a sialyltransferase from bovine colostrum by affinity chromatography on CDP-agarose. J Biol Chem 1977;252:2356-2362.
73. Griffiths J, Reynolds S. Plasma sialyl transferase total and isoenzyme activity in the diagnosis of cancer of the colon. Clin Biochem 1982;15:46-48.
74. Gessner P, Riedl S, Quentmaier A, Kemmner W. Enhanced activity of CMP-neuAc:Gal beta 1-4GlcNAc:alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer Lett 1993;75:143-149.
75. Lee M, Park JJ, Ko YG, Lee YS. Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-anchored ST6Gal I-mediated sialylation of integrin β1 and migration in colon cancer cells. Radiat Oncol 2012;7:47.
76. Weiser MM, Wilson Jr. Serum levels of glycosyltransferases and related glycoproteins as indicators of cancer: biological and clinical implications. Crit Rev Clin Lab Sci 1981;14:189-239.
77. Strous GJ. Golgi and secreted galactosyltransferase. CRC Crit Rev Biochem 1986;21:119-151.
78. Cho SK, Cummings RD. A soluble form of alpha1,3-galactosyltransferase functions within cells to galactosylate glycoproteins. J Biol Chem 1997;272:13622-13628.
79. Zhu G, Allende ML, Jaskiewicz E, et al. Two soluble glycosyltransferases glycosylate less efficiently in vivo than their membrane bound counterparts. Glycobiology 1998;8:831-840.
80. Miyagi T, Yamaguchi K. Mammalian sialidases: physiological and pathological roles in cellular functions. Glycobiology 2012;22:880-896.
81. Yamanami H, Shiozaki K, Wada T, et al. Down-regulation of sialidase NEU4 may contribute to invasive properties of human colon cancers. Cancer Sci 2007;98:299-307.
82. Uemura T, Shiozaki K, Yamaguchi K, et al. Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene 2009;28:1218-1229.
83. Shiozaki K, Yamaguchi K, Takahashi K, Moriya S, Miyagi T. Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4. J Biol Chem 2011;286:21052-21061.
84. Shiozaki K, Yamaguchi K, Sato I, Miyagi T. Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice. Cancer Sci 2009;100:588-594.
85. Kakugawa Y, Wada T, Yamaguchi K, et al. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci U S A 2002;99:10718-10723.
86. Jass Jr. Heredity and DNA methylation in colorectal cancer. Gut 2007;56:154-155.
87. Jass Jr. Colorectal cancer: a multipathway disease. Crit Rev Oncog 2006;12:273-287.
88. Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 2013;25:177-183.
89. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008;135:1079-1099.
90. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
91. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
92. Takami K, Yana I, Kurahashi H, Nishisho I. Multistep carcinogenesis in colorectal cancers. Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:190-196.
93. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol 2009;656:85-106.
94. Zeichner SB, Raj N, Cusnir M, Francavilla M, Hirzel A. A De Novo Germline APC Mutation (3927del5) in a Patient with Familial Adenomatous Polyposis: Case Report and Literature Review. Clin Med Insights Oncol 2012;6:315-323.
95. Kanthan R, Senger JL, Kanthan SC. Molecular events in primary and metastatic colorectal carcinoma: a review. Patholog Res Int 2012;2012:597497.
96. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011;147:275-292.
97. Gretschel S, Haensch W, Schlag PM, Kemmner W. Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer. Oncology 2003;65:139-145.
98. Schultz MJ, Swindall AF, Wright JW, Sztul ES, Landen CN, Bellis SL. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res 2013;6:25.
99. Lin S, Kemmner W, Grigull S, Schlag PM. Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res 2002;276:101-110.
100. Peyrat JP, Recchi MA, Hebbar M, et al. Regulation of sialyltransferase expression by estradiol and 4-OH-tamoxifen in the human breast cancer cell MCF-7. Mol Cell Biol Res Commun 2000;3:48-52.
101. Mondal S, Chandra S, Mandal C. Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia. Leuk Res 2010;34:463-470.
102. Wang PH, Lee WL, Lee YR, et al. Enhanced expression of alpha 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma. Gynecol Oncol 2003;89:395-401.
103. Lee M, Park JJ, Lee YS. Adhesion of ST6Gal I-mediated human colon cancer cells to fibronectin contributes to cell survival by integrin beta1-mediated paxillin and AKT activation. Oncol Rep 2010;23:757-761.
104. Lee M, Lee HJ, Seo WD, Park KH, Lee YS. Sialylation of integrin beta1 is involved in radiation-induced adhesion and migration in human colon cancer cells. Int J Radiat Oncol Biol Phys 2010;76:1528-1536.
105. Harvey BE, Toth CA, Wagner HE, Steele GD Jr, Thomas P. Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases. Cancer Res 1992;52:1775-1779.
106. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
107. O'Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 2008;13:1074-1083.
108. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 2007;1775:163-180.
109. Bellis SL. Variant glycosylation: an underappreciated regulatory mechanism for beta1 integrins. Biochim Biophys Acta 2004;1663:52-60.
110. Agnantis NJ, Goussia AC, Batistatou A, Stefanou D. Tumor markers in cancer patients: an update of their prognostic significance: Part II. In vivo 2004;18:481-488.
111. Seales EC, Jurado GA, Singhal A, Bellis SL. Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin. Oncogene 2003;22:7137-7145.
112. Dalziel M, Dall'Olio F, Mungul A, Piller V, Piller F. Ras oncogene induces beta-galactoside alpha2,6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter. Eur J Biochem 2004;271:3623-3634.
113. Zhuo Y, Chammas R, Bellis SL. Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. J Biol Chem 2008;283:22177-22185.
114. Zhuo Y, Bellis SL. Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function. J Biol Chem 2011;286:5935-5941.
115. Margadant C, Monsuur HN, Norman JC, Sonnenberg A. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol 2011;23:607-614.
116. Nam JM, Chung Y, Hsu HC, Park CC. beta1 integrin targeting to enhance radiation therapy. Int J Radiat Biol 2009;85:923-928.
117. Cordes N, Park CC. beta1 integrin as a molecular therapeutic target. Int J Radiat Biol 2007;83:753-760.
118. Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol 2013;3:113.
119. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
120. Sandfort V, Koch U, Cordes N. Cell adhesion-mediated radioresistance revisited. Int J Radiat Biol 2007;83:727-732.
121. Cordes N, Meineke V. Cell adhesion-mediated radioresistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther Onkol 2003;179:337-344.
122. Cordes N. Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity. Cancer Res 2004;64:5683-5692.
123. Eke I, Storch K, Krause M, Cordes N. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis. Cancer Res 2013;73:5869-5879.
124. Lee M, Lee HJ, Bae S, Lee YS. Protein sialylation by sialyltransferase involves radiation resistance. Mol Cancer Res 2008;6:1316-1325.
125. Marin JJ, Sanchez de Medina F, Castano B, et al. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev 2012;44:148-172.
126. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-3419.
127. Sobrero A. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol 2006;7:515-516.
128. Cartwright TH. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:155-166.
129. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-2114.
130. Hewish M, Cunningham D. First-line treatment of advanced colorectal cancer. Lancet 2011;377:2060-2062.
131. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-527.
132. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-499.
133. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603.
134. Sartore-Bianchi A, Bencardino K, Cassingena A, et al. Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treat Rev 2010;36 Suppl 3:S1-S5.
135. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507.
136. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J- Min/+ mice. J Biol Chem 2004;279:43261-43272.
137. Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A 2002;99:1521-1526.
138. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010;29:3033-3043.
139. Troiani T, Zappavigna S, Martinelli E, et al. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther 2013;13:241-255.
140. Chen X, Liu Y, Røe OD, et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One 2013;8:e59314.
141. Nagahara H, Mimori K, Ohta M, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005;11:1368-1371.
142. Magne N, Fischel JL, Dubreuil A, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002;86:1518-1523.
143. Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2011;226:2316-2328.
144. Matsumoto K, Yokote H, Arao T, et al. N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 2008;99:1611-1617.
145. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 2006;281:2572-2577.
146. Liu YC, Yen HY, Chen CY, et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci U S A 2011;108:11332-11337.
147. Park JJ, Yi JY, Jin YB, et al. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. Biochem Pharmacol 2012;83:849-857.
148. Boltje TJ, Buskas T, Boons GJ. Opportunities and challenges in synthetic oligosaccharide and glycoconjugate research. Nat Chem 2009;1:611-622.
149. Lairson LL, Henrissat B, Davies GJ, Withers SG. Glycosyltransferases: structures, functions, and mechanisms. Annu Rev Biochem 2008;77:521-555.
150. Breton C, Snajdrova L, Jeanneau C, Koca J, Imberty A. Structures and mechanisms of glycosyltransferases. Glycobiology 2006;16:29R-37R.
151. Wellen KE, Thompson CB. A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol 2012;13:270-276.
152. Koike T, Kimura N, Miyazaki K, et al. Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A 2004;101:8132-8137.
153. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674-687.
154. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
155. Hittelman WN, Liao Y, Wang L, Milas L. Are cancer stem cells radioresistant? Future Oncol 2010;6:1563-1576.
156. Koch U, Krause M, Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures: radiation oncology perspective. Semin Cancer Biol 2010;20:116-124.
157. Box C, Rogers SJ, Mendiola M, Eccles SA. Tumour-microenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol 2010;20:128-138.
158. Wang X, Zhang LH, Ye XS. Recent development in the design of sialyltransferase inhibitors. Med Res Rev 2003;23:32-47.
159. Drinnan NB, Halliday J, Ramsdale T. Inhibitors of sialyltransferases: potential roles in tumor growth and metastasis. Mini Rev Med Chem 2003;3:501-517.
160. Chiang CH, Wang CH, Chang HC, More SV, Li WS, Hung WC. A novel sialyltransferase inhibitor AL10 suppresses invasion and metastasis of lung cancer cells by inhibiting integrin-mediated signaling. J Cell Physiol 2010;223:492-499.
161. Hsu CC, Lin TW, Chang WW, et al. Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. Gynecol Oncol 2005;96:415-422.
162. Rillahan CD, Brown SJ, Register AC, Rosen H, Paulson JC. High-throughput screening for inhibitors of sialyl- and fucosyltransferases. Angew Chem Int Ed Engl 2011;50:12534-12537.
163. Yamamoto H, Oviedo A, Sweeley C, Saito T, Moskal Jr. Alpha2,6-sialylation of cell-surface N-glycans inhibits glioma formation in vivo. Cancer Res 2001;61:6822-6829.
164. Yamamoto H, Kaneko Y, Rebbaa A, Bremer EG, Moskal Jr. alpha2,6-Sialyltransferase gene transfection into a human glioma cell line (U373 MG) results in decreased invasivity. J Neurochem 1997;68:2566-2576.
165. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-542.